Close
Close
Finance News

Oncolytics Biotech to Present at the 2019 Bloom Burton and Co. Healthcare Investor Conference

4.0
4.0 from 1 vote
Tuesday, April 23, 2019

CALGARY, AB and SAN DIEGO, CA - Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, announced that it would present at the 2019 Bloom Burton & Co. Investor Conference. The presentation, by Dr. Matt Coffey, President & CEO of Oncolytics, will take place at 11:00 am ET, on Tuesday, April 30, 2019, at the Metro Toronto Convention Centre, Toronto, Ontario.

A live audio link to the webcast session will be available on the Company's website at http://www.oncolyticsbiotech.com/investor-centre/presentations. It is recommended that listeners log on 10 minutes in advance of the live session to register and download any necessary software. An audio replay will be accessible approximately two hours following the presentation on the Oncolytics website.

About Oncolytics Biotech Inc.

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype - turning "cold" tumors "hot" - through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer. For further information, please visit:  ww.oncolyticsbiotech.com.

Company Contact

Michael Moore
Vice President, Investor Relations & Corporate Communications
858-886-7813
mmoore@oncolytics.ca

Investor Relations

Timothy McCarthy
LifeSci Advisors
212.915.2564
tim@lifesciadvisors.com

Media Contact

Jason Spark
Canale Communications
619-849-6005
jason@canalecomm.com

Source: Oncolytics Biotech Inc
4.0
4.0 from 1 vote
Free Newsletter
Trending News
Videos
by Abidemi Uruejoma
45 views
by Abidemi Uruejoma
63 views
by Abidemi Uruejoma
67 views